P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review

Journal of Advanced Research

Volumn 6, Issue 1, 2015, Pages 45-62

  Abdallah, Hossam M ^a,b   Al Abd, Ahmed M ^a,c   El Dine, Riham Salah ^b   El Halawany, Ali M ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Multidrug resistance (MDR); Multidrug resistance associated protein 1 (MRP1); Natural products; P gp (P glycoprotein)

Indexed keywords

EID: 84920199062     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2014.11.008     Document Type: Review

References (130)

1. Ling V., Thompson L.H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974, 83(1):103-116.
2. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11(4):265-283.
3. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47(3):381-389.
4. Lee C.H., Bradley G., Zhang J.T., Ling V. Differential expression of P-glycoprotein genes in primary rat hepatocyte culture. J Cell Physiol 1993, 157(2):392-402.
5. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84(21):7735-7738.
6. Sugawara I., Nakahama M., Hamada H., Tsuruo T., Mori S. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170,000-180,000 P-glycoprotein. Cancer Res 1988, 48(16):4611-4614.
7. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86(2):695-698.
8. Arceci R.J., Croop J.M., Horwitz S.B., Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988, 85(12):4350-4354.
9. Kawai K., Kusano I., Ido M., Sakurai M., Shiraishi T., Yatani R. Identification of a P-glycoprotein-related protein (mini-P-glycoprotein) which is overexpressed in multidrug resistant cells. Biochem Biophys Res Commun 1994, 198(2):804-810.
10. Young L.C., Campling B.G., Cole S.P., Deeley R.G., Gerlach J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001, 7(6):1798-1804.
11. Zeng H., Bain L.J., Belinsky M.G., Kruh G.D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999, 59(23):5964-5967.
12. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000, 92(20):1651-1656.
13. Ross D.D., Karp J.E., Chen T.T., Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000, 96(1):365-368.
14. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999, 59(18):4559-4563.
15. Gollapudi S., Thadepalli F., Kim C.H., Gupta S. Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Oncol Res 1995, 7(5):213-225.
16. Louisa M., Soediro T.M., Suyatna F.D. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev 2014, 15(4):1639-1642.
17. Kawabata S., Oka M., Shiozawa K., Tsukamoto K., Nakatomi K., Soda H., et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001, 280(5):1216-1223.
18. Xie N., Mou L., Yuan J., Liu W., Deng T., Li Z., et al. Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference. PLoS ONE 2014, 9(7):e103463.
19. Horio M., Lovelace E., Pastan I., Gottesman M.M. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles. Biochim Biophys Acta 1991, 1061(1):106-110.
20. Horio M., Chin K.V., Currier S.J., Goldenberg S., Williams C., Pastan I., et al. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 1989, 264(25):14880-14884.
21. Sharom F.J., Yu X., Doige C.A. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 1993, 268(32):24197-24202.
22. Roepe P.D. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992, 31(50):12555-12564.
23. Roepe P.D., Wei L.Y., Cruz J., Carlson D. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993, 32(41):11042-11056.
24. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase?. Trends Biochem Sci 1992, 17(1):18-21.
25. Ford J.M. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995, 9(2):337-361.
26. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
27. Cornwell M.M., Safa A.R., Felsted R.L., Gottesman M.M., Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 1986, 83(11):3847-3850.
28. Safa A.R., Glover C.J., Meyers M.B., Biedler J.L., Felsted R.L. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 1986, 261(14):6137-6140.
29. Urbatsch I.L., al-Shawi M.K., Senior A.E. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 1994, 33(23):7069-7076.
30. Xiang Q.F., Zhang D.M., Wang J.N., Zhang H.W., Zheng Z.Y., Yu D.C., et al. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Liver Int 2014.
31. Sen R., Natarajan K., Bhullar J., Shukla S., Fang H.B., Cai L., et al. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 2012, 11(9):2033-2044.
32. Lum B.L., Gosland M.P. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 1995, 9(2):319-336.
33. Bradley G., Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994, 13(2):223-233.
34. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992, 79(2):473-476.
35. Niehans G.A., Jaszcz W., Brunetto V., Perri R.T., Gajl-Peczalska K., Wick M.R., et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992, 52(13):3768-3775.
36. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84(1):265-269.
37. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41(5):1967-1972.
38. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982, 42(11):4730-4733.
39. Al-Abd A.M., Mahmoud A.M., El-Sherbiny G.A., El-Moselhy M.A., Nofal S.M., El-Latif H.A., et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 2011, 44(6):591-601.
40. Schuurhuis G.J., Broxterman H.J., van der Hoeven J.J., Pinedo H.M., Lankelma J. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil. Cancer Chemother Pharmacol 1987, 20(4):285-290.
41. Hollt V., Kouba M., Dietel M., Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992, 43(12):2601-2608.
42. Sehested M., Jensen P.B., Skovsgaard T., Bindslev N., Demant E.J., Friche E., et al. Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators. Br J Cancer 1989, 60(6):809-814.
43. Lampidis T.J., Krishan A., Planas L., Tapiero H. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv 1986, 3(4):251-259.
44. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000, 60(11):2964-2972.
45. Spoelstra E.C., Dekker H., Schuurhuis G.J., Broxterman H.J., Lankelma J. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 1991, 41(3):349-359.
46. Chao N.J., Aihara M., Blume K.G., Sikic B.I. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. Exp Hematol 1990, 18(11):1193-1198.
47. Nawrath H., Raschack M. Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle. J Pharmacol Exp Ther 1987, 242(3):1090-1097.
48. Pirker R., Keilhauer G., Raschack M., Lechner C., Ludwig H. Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 1990, 45(5):916-919.
49. Kessel D., Wilberding C. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs. Cancer Treat Rep 1985, 69(6):673-676.
50. Alaoui-Jamali M.A., Schecter R.L., Rustum Y.M., Centurioni M.G., Lehnert S., Batist G. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. J Pharmacol Exp Ther 1993, 264(3):1299-1304.
51. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991, 51(16):4226-4233.
52. Jonsson B., Nilsson K., Nygren P., Larsson R. SDZ PSC-833 - a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs 1992, 3(6):641-646.
53. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996, 56(18):4171-4179.
54. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53(19):4595-4602.
55. Dale I.L., Tuffley W., Callaghan R., Holmes J.A., Martin K., Luscombe M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 1998, 78(7):885-892.
56. Mullin S., Mani N., Grossman T.H. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother 2004, 48(11):4171-4176.
57. Kannan P., Telu S., Shukla S., Ambudkar S.V., Pike V.W., Halldin C., et al. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci 2011, 2(2):82-89.
58. Michalak K., Wesołowska O. Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins. Anti-Cancer Agents Med Chem 2012, 12(8):880-890.
59. Bansal T., Jaggi M., Khar R., Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharmaceut Sci 2009, 12(1):46-78.
60. Pick A., Müller H., Mayer R., Haenisch B., Pajeva I.K., Weigt M., et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 2011, 19(6):2090-2102.
61. Farabegoli F., Papi A., Bartolini G., Ostan R., Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010, 17(5):356-362.
62. Wesołowska O., Wiśniewski J., Środa K., Krawczenko A., Bielawska-Pohl A., Paprocka M., et al. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol 2010, 644(1):32-40.
63. Sun L., Chen W., Qu L., Wu J., Si J. Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression. Mol Med Rep 2013, 8(6):1883-1887.
64. Li C., Kim M., Choi H., Choi J. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res 2011, 34(11):1965-1972.
65. Zhang S., Morris M.E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003, 20(8):1184-1191.
66. Zhang S., Morris M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exper Therap 2003, 304(3):1258-1267.
67. Nguyen H., Zhang S., Morris M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003, 92(2):250-257.
68. Romiti N., Tramonti G., Donati A., Chieli E. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 2004, 76(3):293-302.
69. Borska S., Chmielewska M., Wysocka T., Drag-Zalesinska M., Zabel M., Dziegiel P. In vitro effect of quercetin on human gastric carcinoma: targeting cancer cells death and MDR. Food Chem Toxicol 2012, 50(9):3375-3383.
70. Choi J.-S., Piao Y.-J., Kang K.W. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011, 34(4):607-613.
71. He L., Zhao C., Yan M., Zhang L.Y., Xia Y.Z. Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier. Phytother Res 2009, 23(7):933-937.
72. Patanasethanont D., Nagai J., Yumoto R., Murakami T., Sutthanut K., Sripanidkulchai B.O., et al. Effects of Kaempferia parviflora extracts and their flavone constituents on p-glycoprotein function. J Pharm Sci 2007, 96(1):223-233.
73. Patanasethanont D., Nagai J., Matsuura C., Fukui K., Sutthanut K., Sripanidkulchai Bo, et al. Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur J Pharmacol 2007, 566(1-3):67-74.
74. Lee E., Enomoto R., Koshiba C., Hirano H. Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. Ann N Y Acad Sci 2009, 1171:132-136.
75. Al-Abd A., Mahmoud A., El-Sherbiny G., El-Moselhy M., Nofal S., El-Latif H., et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 2011, 44(6):591-601.
76. Kim M.K., Choo H., Chong Y. Water-soluble and cleavable quercetin-amino Acid conjugates as safe modulators for p-glycoprotein-based multidrug resistance. J Med Chem 2014, 57(17):7216-7233.
77. Raad I., Terreux R., Richomme P., Matera E.-L., Dumontet C., Raynaud J., et al. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. Bioorg Med Chem 2006, 14(20):6979-6987.
78. Kimura S., Ito C., Jyoko N., Segawa H., Kuroda J., Okada M., et al. Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from Calophyllum brasiliense that acts by induction of apoptosis. Int J Cancer 2005, 113(1):158-165.
79. Shen X., Chen G., Zhu G., Fong W.F. (±)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (±)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Bioorg Med Chem 2006, 14(21):7138-7145.
80. Song J.S., Chae J.W., Lee K.R., Lee B.H., Choi E.J., Ahn S.H., et al. Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats. Xenobiotica 2011, 41(10):895-902.
81. Hanafi-Bojd M.Y., Iranshahi M., Mosaffa F., Tehrani S.O., Kalalinia F., Behravan J. Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines. Planta Med 2011, 77(14):1590-1593.
82. Ferreira M.-J.U. A new sesquiterpene-coumarin ether and a new abietane diterpene and their effects as inhibitors of P-glycoprotein. Planta Med 2004, 70:828-833.
83. Ohnishi A., Matsuo H., Yamada S., Takanaga H., Morimoto S., Shoyama Y., et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. British J Pharmacol 2000, 130(6):1369-1377.
84. Barthomeuf C., Grassi J., Demeule M., Fournier C., Boivin D., Beliveau R. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chem Pharmacol 2005, 56(2):173-181.
85. Cortés-Selva F., Jiménez I.A., Muñoz-Martínez F., Campillo M., Bazzocchi I.L., Pardo L., et al. Dihidro-β-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania. Curr Pharm Des 2005, 11(24):3125-3159.
86. Reyes C.P., Muñoz-Martínez F., Torrecillas I.R., Mendoza C.R., Gamarro F., Bazzocchi I.L., et al. Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-β-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance. J Med Chem 2007, 50(20):4808-4817.
87. Steglich B., Mahringer A., Li Y., Posner G.H., Fricker G., Efferth T. Inhibition of P-glycoprotein by two artemisinin derivatives. Nat Prod Bioprosp 2012, 2(2):59-64.
88. Legault J., Pichette A. Potentiating effect of β-caryophyllene on anticancer activity of α-humulene, isocaryophyllene and paclitaxel. J Pharm Pharmacol 2007, 59(12):1643-1647.
89. Min Y.D., Kwon H.C., Yang M.C., Lee K.H., Choi S.U., Lee K.R. Isolation of limonoids and alkaloids from Phellodendron amurense and their multidrug resistance (MDR) reversal activity. Arch Pharm Res 2007, 30(1):58-63.
90. Molnár J., Gyémánt N., Tanaka M., Hohmann J., Bergmann-Leitner E., Molnár P., et al. Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr Pharm Des 2006, 12(3):287-311.
91. Duarte N., Járdánházy A., Molnár J., Hilgeroth A., Ferreira M.-J.U. Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells. Bioorg Med Chem 2008, 16(20):9323-9330.
92. Duarte N., Varga A., Cherepnev G., Radics R., Molnár J., Ferreira M.-J.U. Apoptosis induction and modulation of P-glycoprotein mediated multidrug resistance by new macrocyclic lathyrane-type diterpenoids. Bioorg Med Chem 2007, 15(1):546-554.
93. Appendino G., Porta C.D., Conseil G., Sterner O., Mercalli E., Dumontet C., et al. A new P-glycoprotein inhibitor from the caper spurge (Euphorbia lathyris). J Nat Prod 2003, 66(1):140-142.
94. Corea G., Di Pietro A., Dumontet C., Fattorusso E., Lanzotti V. Jatrophane diterpenes from Euphorbia spp. as modulators of multidrug resistance in cancer therapy. Phytochem Rev 2009, 8(2):431-447.
95. Valente I., Reis M., Duarte N., Serly J., Molnár J., Ferreira M.J.U. Jatrophane diterpenes from Euphorbia mellifera and their activity as P-glycoprotein modulators on multidrug-resistant mouse lymphoma and human colon adenocarcinoma cells. J Nat Prod 2012, 75(11):1915-1921.
96. Ferreira M.J.U., Gyémánt N., Madureira A.M., Molnár J. Inhibition of P-glycoprotein transport activity in a resistant mouse lymphoma cell line by diterpenic lactones. Anticancer Res 2005, 25(5):3259-3262.
97. Madureira A.M., Gyémánt N., Ascenso J.R., Abreu P.M., Molnár J., Ferreira M.J.U. Euphoportlandols A and B, tetracylic diterpene polyesters from Euphorbia portlandica and their anti-MDR effects in cancer cells. J Nat Prod 2006, 69(6):950-953.
98. Lei Y., Tan J., Wink M., Ma Y., Li N., Su G. An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo WT Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1. Food Chem 2013, 136(3):1117-1121.
99. Ma Y., Wink M. Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine 2008, 15(9):754-758.
100. Pearce H., Safa A.R., Bach N., Winter M., Cirtain M.C., Beck W.T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci 1989, 86(13):5128-5132.
101. Fu L.W., Deng Z.A., Pan Q.C., Fan W. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids. Anticancer Res 2001, 21(4 A):2273-2280.
102. Ikeda R., Che X.F., Yamaguchi T., Ushiyama M., Zheng C.L., Okumura H., et al. Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci 2005, 96(6):372-376.
103. Chávez D., Cui B., Chai H.B., García R., Mejía M., Farnsworth N.R., et al. Reversal of multidrug resistance by tropane alkaloids from the stems of Erythroxylum rotundifolium. J Nat Prod 2002, 65(4):606-610.
104. Mi Q., Cui B., Chávez D., Chai H., Zhu H., Cordell G.A., et al. Characterization of tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype. Anticancer Res 2002, 22(3):1385-1398.
105. Mi Q., Cui B., Silva G.L., Lantvit D., Lim E., Chai H., et al. Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay. Cancer Lett 2002, 184(1):13-20.
106. Mi Q., Cui B., Lantvit D., Reyes-Lim E., Chai H., Pezzuto J.M., et al. Pervilleine F, a new tropane alkaloid aromatic ester that reverses multidrug resistance. Anticancer Res 2003, 23(5 A):3607-3615.
107. Silva G.L., Cui B., Chávez D., You M., Chai H.B., Rasoanaivo P., et al. Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei. J Nat Prod 2001, 64(12):1514-1520.
108. Ivanova A., Serly J., Christov V., Stamboliyska B., Molnar J. Alkaloids derived from genus Veratrum and Peganum of Mongolian origin as multidrug resistance inhibitors of cancer cells. Fitoterapia 2011, 82(4):570-575.
109. Kam T.-S., Subramaniam G., Sim K.-M., Yoganathan K., Koyano T., Toyoshima M., et al. Reversal of multidrug resistance (MDR) by aspidofractinine-type indole alkaloids. Bioorg Med Chem Lett 1998, 8(19):2769-2772.
110. Rho M.C., Toyoshima M., Hayashi M., Koyano T., Subramaniam G., Kam T.S., et al. Reversal of multidrug resistance by kopsiflorine isolated from Kopsia dasyrachis. Planta Med 1999, 65(4):307-310.
111. Nguyen V.T.B., Darbour N., Bayet C., Doreau A., Raad I., Phung B.H., et al. Selective modulation of P-glycoprotein activity by steroidal saponines from Paris polyphylla. Fitoterapia 2009, 80(1):39-42.
112. Ramalhete C., Molnár J., Mulhovo S., Rosário V.E., Ferreira M.-J.U. New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorg Med Chem 2009, 17(19):6942-6951.
113. Choi C.H., Kang G., Min Y.D. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 2003, 69(3):235-240.
114. Hu Y.J., Shen X.L., Lu H.L., Zhang Y.H., Huang X.A., Fu L.C., et al. Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells. J Nat Prod 2008, 71(6):1049-1051.
115. Huang C., Xu D., Xia Q., Wang P., Rong C., Su Y. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol 2012, 64(12):1741-1750.
116. Risinger A.L., Jackson E.M., Polin L.A., Helms G.L., LeBoeuf D.A., Joe P.A., et al. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 2008, 68(21):8881-8888.
117. Manda V.K., Dale O.R., Awortwe C., Ali Z., Khan I.A., Walker L.A., et al. Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. Front Pharmacol 2014, 5:178.
118. Eichhorn T., Efferth T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 2012, 141(2):557-570.
119. Tran T.P., Kim H.G., Choi J.H., Na M.K., Jeong H.G. Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7/adriamycin cells. Phytomedicine 2013, 20(7):622-631.
120. Chung S.Y., Han A.R., Sung M.K., Jung H.J., Nam J.W., Seo E.K., et al. Potent modulation of p-glycoprotein activity by naturally occurring phenylbutenoids from Zingiber cassumunar. Phytother Res 2009, 23(4):472-476.
121. Rubis B., Polrolniczak A., Knula H., Potapinska O., Kaczmarek M., Rybczynska M. Phytosterols in physiological concentrations target multidrug resistant cancer cells. Med Chem 2010, 6(4):184-190.
122. Holland M., Panetta J., Hoskins J., Bebawy M., Roufogalis B., Allen J., et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 2006, 71(8):1146-1154.
123. Eid S.Y., El-Readi M.Z., Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine 2012, 19(11):977-987.
124. Chearwae W., Anuchapreeda S., Nandigama K., Ambudkar S.V., Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 2004, 68(10):2043-2052.
125. Saab A.M., Guerrini A., Sacchetti G., Maietti S., Zeino M., Arend J., et al. Phytochemical analysis and cytotoxicity towards multidrug-resistant leukemia cells of essential oils derived from lebanese medicinal plants. Planta Med 2012, 78(18):1927-1931.
126. Lai K.C., Kuo C.L., Ho H.C., Yang J.S., Ma C.Y., Lu H.F., et al. Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo. Phytomedicine 2012, 19(7):625-630.
127. Romiti N., Pellati F., Nieri P., Benvenuti S., Adinolfi B., Chieli E. P-glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line. Planta Med 2008, 74(3):264-266.
128. Yan M., Nuriding H. Reversal effect of vitamin D on different multidrug-resistant cells. Genet Mol Res 2014, 13(3):6239-6247.
129. Khalil Z.G., Huang X.C., Raju R., Piggott A.M., Capon R.J., Shornephine A. Structure, chemical stability, and P-glycoprotein inhibitory properties of a rare diketomorpholine from an Australian marine-derived Aspergillus sp. J Org Chem 2014, 79(18):8700-8705.
130. Huang X.C., Xiao X., Zhang Y.K., Talele T.T., Salim A.A., Chen Z.S., et al. Lamellarin O, a pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells. Mar Drugs 2014, 12(7):3818-3837.